Society for Biological Engineering Debuts Translational Medicine and Bioengineering Conference

Meeting will focus on clinical and commercial applications of biological technologies, Nov. 12–13, in San Francisco, CA
September 26, 2016

The Society for Biological Engineering (SBE) — a technical subsidiary of the American Institute of Chemical Engineers (AIChE) — will unite researchers and practitioners in fields related to biotechnology and biomedicine at its first Translational Medicine and Bioengineering Conference. The conference will take place Nov. 12–13 in San Francisco, California, in connection with AIChE’s Annual Meeting Nov. 13–18.

This inaugural conference coincides with the launch in 2016 of the organization’s Bioengineering and Translational Medicine journal (BioTM), an open-access journal of AIChE and SBE published by John Wiley & Sons and edited by Samir Mitragotri of the University of California, Santa Barbara.

Like the BioTM journal, the Translational Medicine and Bioengineering Conference will focus on the fundamental ways that chemical and biological engineering approaches drive innovative technologies and provide solutions that impact clinical medical practice, as well as the development of commercial health care products. The meeting offers a venue where researchers and trainees can collaborate on the translation of biological technologies from the laboratory to clinical and commercial ventures. Topics to be discussed include biopharmaceuticals, gene and drug delivery, biomanufacturing, stem cells and regenerative medicine, as well as entrepreneurship in the biomedical field.

In announcing the conference, AIChE Executive Director June Wispelwey said “The Translational Medicine and Bioengineering Conference will showcase the immensely important contributions that chemical and biological engineers are bringing to health care, with applications that affect the quality of life for everyone.”

Wispelwey added that the conference is the latest entry in AIChE’s and SBE’s portfolio of programs serving the interests of engineers, researchers and their collaborators in the crucial bioengineering sector.

The first Translational Medicine and Bioengineering Conference is co-chaired by Ravi Kane, a professor and the GRA Eminent Scholar in Cancer Nanotechnology at the Georgia Institute of Technology (Georgia Tech), and Mark Prausnitz, a professor of chemical and biomolecular engineering and director of the Center for Drug Design, Development and Delivery at Georgia Tech.

Complete program information, including registration details, can be found at aiche.org/translational.

About SBE:

Established in 2004, the Society for Biological Engineering is a technological community for engineers and applied scientists integrating biology with engineering. Members of SBE come from a broad spectrum of industries and disciplines and share in SBE’s mission of realizing the benefits of bioprocessing, biomedical and biomolecular applications. Learn more about SBE’s programs and activities at www.aiche.org/sbe.

About AIChE:

AIChE is a professional society of more than 53,000 chemical engineers in 110 countries. Its members work in corporations, universities and government using their knowledge of chemical processes to develop safe and useful products for the benefit of society. Through its varied programs, AIChE continues to be a focal point for information exchange on the frontiers of chemical engineering research in such areas as energy, sustainability, biological and environmental engineering, nanotechnology and chemical plant safety and security. More information about AIChE is available at www.aiche.org.